anti-egfr

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Anti-EGFR Antibody (D2C7) is a monoclonal antibody targeting EGFR. The recombinant immunotoxin D2C7-(scdsFv)-PE38KDEL, developed from Anti-EGFR Antibody (D2C7), exhibits antitumor activity in glioblastoma models.

Anti-EGFR Antibody (1M661) is a Rabbit IgG monoclonal antibody targeting Human EGFR.

Anti-EGFR Antibody (1X807) is a Rabbit IgG monoclonal antibody targeting Human EGFR.

Anti-EGFR Antibody (AVID100 Naked Antibody) is an antibody targeting EGFR and can be used to generate the ADC AVID100. Anti-EGFR Antibody (AVID100 Naked Antibody) can be used for oncology research.

Anti-EGFR Antibody (HTI-1511 Naked Antibody) is an antibody targeting EGFR and can be used to generate the ADC HTI-1511. Anti-EGFR Antibody (HTI-1511 Naked Antibody) can be used for oncology research.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

Imgatuzumab (RG 7160; GA201) is a humanized, glycoengineered IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This product inhibits EGFR-mediated signaling (such as MAPK and PI3K pathways) by blocking EGF binding and inducing receptor internalization. As a glycoengineered antibody, Imgatuzumab features enhanced affinity for Fc gamma RIIIa, resulting in potent antibody-dependent cellular cytotoxicity (ADCC). It is used to research EGFR-overexpressing solid tumors and demonstrates synergistic effects when combined with chemotherapeutic agents.

Anti-ERBB1/EGFR/HER1 Antibody 2 is an antibody targeting ERBB1/EGFR/HER1. It can be used for oncology, immunology, and antibody drug development research.

Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer.

RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways.

SU11652 is an effective and competitive receptor tyrosine kinase (RTK) inhibitor, including VEGFR, FGFR, PDGFR, and Kit. SU11652 disrupts the function of all forms of mutant Kit and may be used in the study of cancers involving Kit mutations.

Daphnetin (7,8-Dihydroxycoumarin), a natural coumarin derivative, is a protein kinase inhibitor with inhibitory for EGFR (IC50: 7.67 μM), PKA (IC50: 9.33 μM), and PKC (IC50: 25.01 μM), also exhibit anti-oxidant and anti-inflammatory activities.

Chalcone (Cinnamophenone) is an aromatic ketone that forms the central core for a variety of important biological compounds, which are known collectively as chalcones.

Anti-ERBB1/EGFR/HER1 Antibody (7A7) is an inhibitory antibody that targets human ERBB1/EGFR/HER1 and can be used in research on EGFR-related cancers.

DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumor activity, which also inhibits EGFR and HER2, and is useful for studying pancreatic cancer.

JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858

Allitinib (AST-1306) (AST-1306) has anti-cancer activity,and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1]

NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.

ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.

EGFR/VEGFR2-IN-1 (Compound 10e) serves as an inhibitor for VEGFR-2 and EGFR, with respective IC50 values of 0.26 and 0.14 μM. It inhibits microtubule protein polymerization with an IC50 of 40.9 μM and induces cell apoptosis (Apoptosis). EGFR/VEGFR2-IN-1 is applicable in research related to anti-leukemia and anti-lymphoma treatments.

Sevabertinib (BAY 2927088) is a selective, potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with anti-tumor activity, used in the study of non-small cell lung cancer.

EGFR-IN-131 (compound 3a) is an efficacious EGFR inhibitor capable of crossing the blood-brain barrier, with an IC50 value of 272.9 nM. This compound exhibits anti-proliferative activity, induces cellular apoptosis (apoptosis), and causes cell cycle arrest in the G0/G1 phase. Additionally, EGFR-IN-131 reduces the protein expression of p-EGFR.